Astrazeneca (AZN) Non Operating Interest Expenses (2009 - 2026)

Astrazeneca's Non Operating Interest Expenses history runs 18 years deep, the most recent figure standing at -$393.0 million for Q1 2026.

• In Q1 2026, Non Operating Interest Expenses fell 12.61% year-over-year to -$393.0 million; the TTM figure through Mar 2026 stood at -$1.7 billion (down 4.29% YoY), while the FY2025 annual figure was -$1.7 billion, up 2.76% from the prior year.
• Non Operating Interest Expenses for Q1 2026 stood at -$393.0 million, up from -$484.0 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was -$311.0 million in Q2 2022, with the low at -$945.0 million in Q4 2023.
• The 5-year median for Non Operating Interest Expenses is -$413.0 million (2024), against an average of -$430.6 million.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses plunged 162.5% in 2023, then jumped 54.6% in 2024.
• Astrazeneca's Non Operating Interest Expenses stood at -$360.0 million in 2022, then slumped by 162.5% to -$945.0 million in 2023, then jumped by 54.6% to -$429.0 million in 2024, then fell by 12.82% to -$484.0 million in 2025, then increased by 18.8% to -$393.0 million in 2026.
• Business Quant data shows AZN's Non Operating Interest Expenses at -$393.0 million in Q1 2026, -$484.0 million in Q4 2025, and -$434.0 million in Q3 2025.